What is the current Somatostatin Analogs market size?

The Somatostatin Analogs market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Somatostatin Analogs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Somatostatin Analogs market?

Increasing demand for targeted therapies drives the Somatostatin Analogs market growth.

What are the major challenges facing the Somatostatin Analogs market?

High development costs and regulatory hurdles challenge the Somatostatin Analogs market.

Which regions lead the Somatostatin Analogs market?

North America and Europe are the leading regions in the Somatostatin Analogs market.

Who are the top companies in the Somatostatin Analogs market?

Novartis and Pfizer are among the top companies in the Somatostatin Analogs market.

What future opportunities exist in the Somatostatin Analogs market?

Emerging markets and new indications offer future opportunities in the Somatostatin Analogs market.

How does technology impact the Somatostatin Analogs market?

Advances in drug delivery technology enhance the Somatostatin Analogs market future outlook.

What is the current regulatory landscape for Somatostatin Analogs?

Stringent regulations and safety standards govern the Somatostatin Analogs market.

What is the future outlook for the Somatostatin Analogs market?

The Somatostatin Analogs market is expected to experience steady growth due to increasing demand.

Somatostatin Analogs Industry Size, Share & Growth Forecast 2033

Somatostatin Analogs by Application (Acromegaly, Carcinoid Syndrome, Neuroendocrine Tumor, Cushing Syndrome, Others), by Types (Octreotide, Lanreotide, Pasireotide), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Somatostatin Analogs Market Size | CAGR 7.2 Forecast 2033

Somatostatin Analogs Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Somatostatin Analogs Market Overview

The Somatostatin Analogs market refers to the industry sector focused on the development and distribution of somatostatin analogs, which are synthetic peptides used to treat various medical conditions, including acromegaly, gastroenteropancreatic neuroendocrine tumors, and diarrhea. As the global Somatostatin Analogs market size is estimated to be around $8.5 billion, the growth outlook and market forecast indicate a significant industry expansion, driven by increasing demand for effective treatments and rising awareness about hormonal disorders. The scope of this market encompasses synthetic peptides, hormone therapies, and pharmaceuticals, with key players focusing on research and development, clinical trials, and regulatory approvals. According to recent studies, the current Somatostatin Analogs market size is approximately $8.5 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of around 7-8% during the forecast period.

Loading chart…

The Somatostatin Analogs market is shaped by key forces such as technology shifts, regulatory frameworks, and competitive intensity. The largest region in the Somatostatin Analogs market is North America, while the fastest-growing region is Asia-Pacific, driven by increasing healthcare expenditure and growing demand for hormone therapies. As the market continues to evolve, players must navigate supply-chain dynamics, consumer behavior, and macroeconomic trends to capitalize on growth opportunities and maintain a competitive edge. With the global Somatostatin Analogs market poised for significant growth, strategic planners, business development teams, and C-suite executives must stay informed about the latest market trends, growth outlook, and industry expansion to make informed decisions and drive business success.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	22.32 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Peptron; Chiasma; Ipsen Biopharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Somatostatin Analogs market is poised for significant growth, driven by increasing demand for effective treatments of hormonal disorders and certain types of cancer. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Advancements in medical technology have led to the development of more potent and longer-acting Somatostatin Analogs, enhancing patient outcomes and driving growth in the Somatostatin Analogs market size. This has been particularly evident in the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors.

The expanding prevalence of hormonal disorders and certain cancers is fueling the need for effective therapies, contributing to a positive growth forecast for the Somatostatin Analogs market. As the global population ages, the incidence of these conditions is expected to increase, further bolstering demand for Somatostatin Analogs.

Restraints2 items

High development costs and stringent regulatory requirements pose significant barriers to entry for new players in the Somatostatin Analogs market, potentially limiting the growth of the Somatostatin Analogs market size. These factors can also impede innovation, as smaller companies may find it challenging to invest in research and development.

Side effects associated with Somatostatin Analogs, such as gastrointestinal disturbances and gallstones, can impact patient compliance and satisfaction, thereby affecting the overall growth forecast of the Somatostatin Analogs market. Manufacturers must invest in educating healthcare providers and patients about these risks to mitigate their impact.

Opportunities2 items

Emerging markets present untapped opportunities for the Somatostatin Analogs market, as these regions often have less stringent regulatory environments and a growing demand for advanced healthcare solutions. Companies can capitalize on these opportunities by adapting their products and marketing strategies to local needs.

The development of novel delivery systems and formulations, such as depot injections, can enhance patient convenience and adherence, driving growth in the Somatostatin Analogs market. This can also lead to increased market share for companies that successfully innovate in this area.

Challenges2 items

Pricing pressures and reimbursement challenges can significantly impact the profitability of companies operating in the Somatostatin Analogs market. As healthcare systems face budget constraints, manufacturers must demonstrate the value of their products to secure favorable reimbursement terms.

The Somatostatin Analogs market is characterized by intense competition, with several established players vying for market share. To remain competitive, companies must invest in research and development, marketing, and strategic partnerships, all while navigating the complexities of the global regulatory landscape.

Market Segmentation

Loading chart…

The Application segment of the Somatostatin Analogs market is a crucial aspect of Somatostatin Analogs segmentation, as it categorizes the market based on the various uses of these analogs. This segment includes applications such as treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and other indications. Each application contributes to the overall market size, with some applications holding a larger share due to higher prevalence or greater demand for effective treatments.

The Types segment of the Somatostatin Analogs market is another key aspect, comprising subtypes such as octreotide, lanreotide, and pasireotide. These subtypes are essential in understanding the market taxonomy of Somatostatin Analogs, as each has its unique characteristics, efficacy, and side effect profile. The market size of each subtype varies based on factors like patient population, competition, and the availability of generic versions, influencing the overall Somatostatin Analogs market size.

Somatostatin Analogs Segmentation Breakdown10 items

Application

Acromegaly

Carcinoid Syndrome

Neuroendocrine Tumor

Cushing Syndrome

Others

Types

Octreotide

Lanreotide

Pasireotide

Regional Insights

Loading chart…

The Somatostatin Analogs market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of Somatostatin Analogs in countries such as China and Japan.

Key drivers for North America include investments in research and development, policies supporting the use of Somatostatin Analogs, and a mature ecosystem. In Europe, drivers include demographics, with an aging population driving demand, infrastructure development, and adoption of Somatostatin Analogs in various therapeutic areas. Asia Pacific is driven by investments in healthcare infrastructure, policies supporting the use of Somatostatin Analogs, and increasing adoption. Latin America and Middle East & Africa are driven by demographics, infrastructure development, and increasing adoption of Somatostatin Analogs.

Regional Drivers5 items

North America: investments, policies, ecosystem maturity

Europe: demographics, infrastructure, adoption

Asia Pacific: investments, policies, adoption

Latin America: demographics, infrastructure, adoption

Middle East & Africa: demographics, infrastructure, adoption

Competitive Landscape

The Somatostatin Analogs market is moderately consolidated, driven by a mix of global players and local companies. The Somatostatin Analogs competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies emphasize distribution and pricing strategies.

Companies in the Somatostatin Analogs market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To overcome these challenges, companies focus on technology, service model, channel strength, customization, and cost advantages. The following companies have adopted distinct strategies:

Novartis: regional expansion

Peptron: vertical integration

Chiasma: premium pricing

Ipsen Biopharmaceutical: OEM tie-ups

Novartis: innovation pipeline

Peptron: local manufacturing

Key Somatostatin Analogs Companies4 items

Novartis

Peptron

Chiasma

Ipsen Biopharmaceutical

Market Ecosystem

The Somatostatin Analogs ecosystem encompasses a complex network of participants, from upstream technology providers to downstream end users, with value created and captured at various stages. The ecosystem can be broadly segmented into three key stages: upstream, midstream, and downstream, with distinct roles and interactions at each stage. Understanding the Somatostatin Analogs ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Somatostatin Analogs

Distributors / channel partners — supply products to healthcare facilities

Service providers / after-sales — offer support and maintenance services

End users / buyers — prescribe and administer Somatostatin Analogs

Regulators/standards bodies — establish and enforce safety and efficacy standards

Data/analytics providers — offer insights on treatment outcomes and market trends

The flow of value in the Somatostatin Analogs ecosystem is influenced by various control points, including regulatory approvals, reimbursement policies, and partnerships between manufacturers and distributors. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Moreover, switching costs and interoperability requirements may affect the ability of end users to adopt different Somatostatin Analogs products. The ecosystem may differ by region, with varying regulatory frameworks, market dynamics, and patient needs, highlighting the need for a nuanced understanding of the Somatostatin Analogs ecosystem.

Recent Industry Insights

The Somatostatin Analogs industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between Ipsen and Illumina, have focused on advancing the diagnosis and treatment of neuroendocrine tumors. Furthermore, the Somatostatin Analogs market has seen notable mergers and acquisitions, including the acquisition of TerSera Therapeutics by Conservation Lab.

In addition, there have been several product launches, such as the introduction of lanreotide formulations for the treatment of acromegaly. Regulatory changes, including the FDA's approval of pasireotide for Cushing's disease, have also impacted the Somatostatin Analogs industry trends. These developments demonstrate a shift in consumer and enterprise trends towards more targeted and effective therapies, driving growth in the Somatostatin Analogs market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Somatostatin Analogs market outlook. The market exhibits moderate attractiveness, driven by increasing demand for effective treatments of hormonal disorders and certain types of cancers. The competitive intensity is relatively high, with key players competing to develop innovative products.

The long-term outlook for the Somatostatin Analogs market is promising, with opportunities for growth in emerging economies and the development of new indications. The innovation landscape is characterized by ongoing research into novel formulations and delivery systems. However, the market is not without risks, including regulatory challenges and supply chain disruptions. Overall, a balanced demand-supply dynamics is expected to prevail, with manufacturers striving to meet the growing demand for these therapies.

11 items

1. Executive Summary

2. Somatostatin Analogs Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Somatostatin Analogs Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Somatostatin Analogs Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Acromegaly

6.1.2. Carcinoid Syndrome

6.1.3. Neuroendocrine Tumor

6.1.4. Cushing Syndrome

6.1.5. Others

6.2. Global Somatostatin Analogs Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Octreotide

6.2.2. Lanreotide

6.2.3. Pasireotide

6.3. Global Somatostatin Analogs Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Somatostatin Analogs Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Somatostatin Analogs Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Somatostatin Analogs Market Competition by Key Manufacturers

8.1. Global Somatostatin Analogs Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Somatostatin Analogs: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Novartis

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Peptron

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chiasma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Ipsen Biopharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Somatostatin Analogs Market

Figure 4: Global Somatostatin Analogs Market: Drivers

Figure 5: Global Somatostatin Analogs Market: Challenges

Figure 6: Global Somatostatin Analogs Market: Trends

Figure 7: Global Somatostatin Analogs Market: Opportunity

Figure 8: Global Somatostatin Analogs Market: Restraint

Figure 9: Global Somatostatin Analogs Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Somatostatin Analogs Market Value (USD Million) By Region

Figure 15: Global Somatostatin Analogs Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Somatostatin Analogs Market Value (USD Million) By Region

Figure 23: Global Somatostatin Analogs Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

61 items

Table 1: Market Segmentation Analysis

Table 2: Global Somatostatin Analogs Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Somatostatin Analogs Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Somatostatin Analogs Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Somatostatin Analogs Market Value (USD Million) By Region

Table 10: Global Somatostatin Analogs Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Somatostatin Analogs Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Somatostatin Analogs Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Somatostatin Analogs Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Novartis Basic Information And Sales Area

Table 31: Novartis. Products Portfolio

Table 32: Peptron Basic Information And Sales Area

Table 33: Peptron. Products Portfolio

Table 34: Chiasma Basic Information And Sales Area

Table 35: Chiasma. Products Portfolio

Table 36: Ipsen Biopharmaceutical Basic Information And Sales Area

Table 37: Ipsen Biopharmaceutical. Products Portfolio

Table 38: Global Market Value (USD Million) (2025-2032) By Application

Table 39: Global Market Share (%) By Application (2032)

Table 40: Global Market Value (USD Million) (2025-2032) By Types

Table 41: Global Market Share (%) By Types (2032)

Table 42: Global Somatostatin Analogs Market Value (USD Million) By Region

Table 43: Global Somatostatin Analogs Market Share (%) By Region (2025-2032)

Table 44: North America Market Value (USD Million) (2025-2032) By Country

Table 45: North America Market Value (USD Million) (2025-2032) By Application

Table 46: North America Market Value (USD Million) (2025-2032) By Types

Table 47: Europe Market Value (USD Million) (2025-2032) By Country

Table 48: Europe Market Value (USD Million) (2025-2032) By Application

Table 49: Europe Market Value (USD Million) (2025-2032) By Types

Table 50: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 51: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 53: South America Market Value (USD Million) (2025-2032) By Country

Table 54: South America Market Value (USD Million) (2025-2032) By Application

Table 55: South America Market Value (USD Million) (2025-2032) By Types

Table 56: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 57: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 59: Research Programs/Design For This Report

Table 60: Key Data Information From Secondary Sources

Table 61: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Somatostatin Analogs Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	22.32 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; Peptron; Chiasma; Ipsen Biopharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options